Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR T-cells in Advanced Lymphoid Malignancies
NCT02529813Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2015
- Primary completion
- Nov 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tisagenlecleucel in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL) and 2 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 30 days. Started Dec 2015; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)Acute Biphenotypic Leukemia (BAL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02529813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02529813.